Condition: Chronic Inflammatory Demyelinating Polyneuropathy · Sponsor: CSL Behring
The pHeNIx study, a national multicentre prospective non-interventional study, should help to describe the conditions of use for Hizentra® and the methods for switching from the IV to SC route in everyday practice, together with the tolerability and efficacy of treatment, which is monitored using a patient application (PRO: Patient-Reported Outcomes).
This description comes directly from the study's public registry record.
Trial Registration Coordinator · +1 610-878-4697 · clinicaltrials@cslbehring.com
Always discuss trial participation with your own doctor first.
| CHU Amiens Picardie 1 | Amiens, France | Not Yet Recruiting |
| CHU Angers | Angers, France | Recruiting |
| Hôpital privé de La Casamance | Aubagne, France | Recruiting |
| CH Bayonne | Bayonne, France | Recruiting |
| Hôpital Pellegrin | Bordeaux, France | Recruiting |
| CHRU Brest | Brest, France | Recruiting |
| Hôpital Henri Mondor | Créteil, France | Recruiting |
| Hôpital Bicêtre | Le Kremlin-Bicêtre, France | Recruiting |
| CH Libourne | Libourne, France | Recruiting |
| Hôpital Roger Salengro, CHU Lille | Lille, France | Recruiting |
| Hôpital Dupuytren | Limoges, France | Recruiting |
| Hôpital Pierre Wertheimer,HCL | Lyon, France | Recruiting |
+ 15 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04672733